SP Funds Trust SP Funds S&P Global Technology ETF (ARCA: SPTE)

最新ニュース SP Funds Trust SP Funds S&P Global Technology ETF (ARCA:SPTE)

The Fund uses a passive management (or indexing) approach to track the performance, before fees and expenses, of the Index. The S&P Global 1200 Shariah Information Technology Capped Index is designed to measure the performance of global large-cap equity securities within the information technology sector that pass rules-based screens for adherence to Shariah investment guidelines, with a cap applied to ensure diversification among companies in the Index..

Taiwan Semiconductor Manufacturing Co. Ltd. Adr ( Tsm )

Nvidia Corp.

Microsoft Corp

Apple Inc

Asml Holding Nv

Sap S.e., ADR

Broadcom Inc

Tokyo Electron Ltd Unspn Adr

Keyence Corp

Shopify Inc.

SP Funds S&P Global Technology ETF

SP Funds Trust SP Funds S&P Global Technology ETF

Marchex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHX#NASDAQ">MCHX</a>) sees Q1 sales of $11.923 million vs $12.13 million analyst estimate.

News

Guidance

MCHX

Marchex Sees Q1 Sales $11.923M vs $12.13M Est

Management

Las Vegas Sands Announces Robert G. Goldstein, Its Chairman And Chief Executive Officer Will Transition To Role Of Senior Advisor On March 1, 2026\

Xtant Medical Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/XTNT#AMEX">XTNT</a>) sees FY2025 sales of $126.000 million-$130.000 million vs $132.85 million analyst estimate.

XTNT

Xtant Medical Hldgs Sees FY2025 Revenue of $126.000M-$130.000M vs $132.85M Est

Marchex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHX#NASDAQ">MCHX</a>) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.02) by 50 percent. The company reported quarterly sales of $11.92 million which missed the analyst consensus estimate of $12.01 million by 0.74 percent. This is a 3.81 percent decrease over sales of $12.39 million the same period last year.

Earnings

Earnings Misses

Marchex Q4 Adj EPS $(0.03) Misses $(0.02) Estimate, Sales $11.92M Miss $12.01M Estimate

Kronos Worldwide (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRO#NYSE">KRO</a>) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $0.11 by 209.09 percent. This is a 140 percent decrease over losses of $(0.05) per share from the same period last year. The company reported quarterly sales of $423.100 million which missed the analyst consensus estimate of $494.264 million by 14.40 percent. This is a 5.75 percent increase over sales of $400.100 million the same period last year.

Kronos Worldwide Q4 2024 GAAP EPS $(0.12) Misses $0.11 Estimate, Sales $423.100M Miss $494.264M Estimate

The Program is expected to be implemented through fiscal year 2026 and deliver gross savings of approximately $350 million by fiscal year 2027 through reductions in the Company's workforce.
In order to achieve this level of cost savings, HPE estimates cash charges of approximately $350 million over the next two years in connection with the Program, with approximately $250 million to be incurred in fiscal year 2025, and the remaining $100 million to be incurred in the fiscal year 2026.
 &nbsp;
&nbsp;

Hewlett Packard Enterprise Board Approved Cost Reduction Program, Estimates Cash Charges Of $350M Over Next Two Years In Connection With Program

CLAR

Clarus Sees FY25 Revenue $250M-$260M vs $285.964M, Sees FY25 Adj. EBITDA $14M-$16M, Adj. EBITDA Margin 5.9% At Midpoint

Elutia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELUT#NASDAQ">ELUT</a>) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.25) by 4 percent. This is a 60.61 percent increase over losses of $(0.66) per share from the same period last year. The company reported quarterly sales of $5.47 million which missed the analyst consensus estimate of $5.90 million by 7.32 percent. This is a 6.93 percent decrease over sales of $5.88 million the same period last year.

ELUT

Elutia Q4 GAAP EPS $(0.26) Misses $(0.25) Estimate, Sales $5.47M Miss $5.90M Estimate

To enhance water safety and reliability for its customers and communities, California Water Service Group (Group) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWT#NYSE">CWT</a>) invested a record $471 million in capital improvements throughout its service areas in 2024. Infrastructure improvements completed last year exceeded the previous high investment recorded in 2023 by $87 million.
Group subsidiary California Water Service's annual Main Replacement Program, the largest portion of the company's infrastructure improvement plans, accounted for $156 million in completed projects. The company installed 189,135 feet of pipe, or nearly 36 miles, in 2024 through this program. Other notable infrastructure projects last year included:
<ul>
<li>124 storage and pressure tank replacements or retrofits to augment available water supplies and regulate fluctuations in water pressure.</li>
<li>110 water treatment facility improvements to continue meeting or surpassing all primary and secondary water quality standards.</li>
<li>27 Supervisory Control and Data Acquisition (SCADA) system upgrades to improve monitoring and efficient operation of facilities throughout the company's service areas.</li>
<li>26 generator and motor control center installations or replacements to help keep systems operating properly during both routine operations and power outages or shutoffs.</li>
</ul>

California Water Service Group Announces It Invested $471M in Capital Improvements Throughout Its Service Areas In 2024

Xtant Medical Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/XTNT#AMEX">XTNT</a>) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $(0.01) by 100 percent. This is a 33.33 percent increase over losses of $(0.03) per share from the same period last year. The company reported quarterly sales of $31.51 million which missed the analyst consensus estimate of $31.80 million by 0.90 percent. This is a 12.11 percent increase over sales of $28.11 million the same period last year.

Xtant Medical Hldgs Q4 EPS $(0.02) Misses $(0.01) Estimate, Sales $31.51M Miss $31.80M Estimate

Profound Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROF#NASDAQ">PROF</a>) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.33) by 39.39 percent. This is a 52.38 percent increase over losses of $(0.42) per share from the same period last year. The company reported quarterly sales of $4.18 million which missed the analyst consensus estimate of $4.27 million by 2.10 percent. This is a 108.85 percent increase over sales of $2.00 million the same period last year.

Earnings Beats

PROF

Profound Medical Q4 EPS $(0.20) Beats $(0.33) Estimate, Sales $4.18M Miss $4.27M Estimate

WIIM

NDLS

Noodles shares are trading higher after the company issued FY25 guidance above estimates.

Clarus Q4 2024 Adj. EPS $(0.08) Misses $0.07 Estimate, Sales $71.4M Beat $69.028M Estimate

Cooper Companies Sees FY25 Adj. EPS $3.94-$4.02 Vs $3.98 Est.; Revenue $4.080B-$4.158B Vs $4.121B Est.

ALX Oncology Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALXO#NASDAQ">ALXO</a>) reported quarterly losses of $(0.44) per share which beat the analyst consensus estimate of $(0.67) by 34.33 percent. This is a 44.3 percent increase over losses of $(0.79) per share from the same period last year.

ALXO

ALX Oncology Holdings Q4 2024 Adj EPS $(0.44) Beats $(0.67) Estimate

AVGO

Broadcom shares are trading higher following better-than-expected Q1 financial results and strong Q2 guidance.

Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) reported quarterly earnings of $4.02 per share which missed the analyst consensus estimate of $4.10 by 1.95 percent. This is a 8.36 percent increase over earnings of $3.71 per share from the same period last year. The company reported quarterly sales of $63.72 billion which beat the analyst consensus estimate of $63.13 billion by 0.93 percent. This is a 9.04 percent increase over sales of $58.44 billion the same period last year.

COST

Costco Wholesale Q2 Adj $4.02 Misses $4.10 Estimate, Sales $63.72B Beat $63.13B Estimate

ARCT

Arcturus Therapeutics shares are trading lower after the company reported Q4 financial results and missed its EPS and revenue estimates.

Noodles (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDLS#NASDAQ">NDLS</a>) sees FY2025 sales of $503.000 million-$512.000 million vs $494.43 million analyst estimate.

Comments

SP Funds Trust SP Funds S&P Global Technology ETF

ニュース

最新ニュース SP Funds Trust SP Funds S&P Global Technology ETF (ARCA:SPTE)

ニュース

パートナーシップ

ベンジンガ・グローバル